---
title: "RDY.US (RDY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RDY.US/news.md"
symbol: "RDY.US"
name: "RDY.US"
parent: "https://longbridge.com/en/quote/RDY.US.md"
datetime: "2026-05-21T07:20:15.181Z"
locales:
  - [en](https://longbridge.com/en/quote/RDY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RDY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RDY.US/news.md)
---

# RDY.US (RDY.US) — Related News

### [Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India](https://longbridge.com/en/news/287073753.md)
*2026-05-20T05:18:36.000Z*
> Dr. Reddy’s Laboratories has launched Obeda, an oral semaglutide biosimilar for type 2 diabetes patients in India. This 

### [Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO](https://longbridge.com/en/news/286680069.md)
*2026-05-17T10:19:56.000Z*
> Dr Reddy's CEO Erez Israeli highlights the company's strategy to grow in the biosimilars and semaglutide markets, antici

### [Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push](https://longbridge.com/en/news/286652907.md)
*2026-05-16T19:17:11.000Z*
> Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada, enhancing its GLP-1 portfolio and com

### [Dr Reddy's Laboratories launches generic Semaglutide injection in Canada](https://longbridge.com/en/news/286635919.md)
*2026-05-15T22:23:19.000Z*
> Dr Reddy's Laboratories has launched its generic Semaglutide injection for type 2 diabetes in Canada, becoming one of th

### [](https://longbridge.com/en/news/286602379.md)
*2026-05-15T18:50:25.000Z*
> Dr. Reddy's Laboratories has launched a semaglutide injection generic in Canada

### [Dr. Reddy's Laboratories Q4 Earnings Call Highlights](https://longbridge.com/en/news/286413791.md)
*2026-05-14T12:09:30.000Z*
> Dr. Reddy's Laboratories reported a resilient FY 2026 performance with record annual revenue despite challenges from low

### [Gohigh News - Factset's latest survey: Dr Reddys Laboratories ADR (RDY-US) EPS estimate revised down to $0.55, estimated target price is $13.27](https://longbridge.com/en/news/286277853.md)
*2026-05-13T14:15:42.000Z*
> According to the latest survey by FactSet, the median EPS estimate for Dr. Reddys Laboratories ADR (RDY-US) for 2027 has

### [Dr Reddy’s revives India business in FY26 with portfolio, productivity reset](https://longbridge.com/en/news/286259855.md)
*2026-05-13T12:17:56.000Z*
> Dr. Reddy’s is focusing on India as a growth engine, achieving a turnaround in its domestic business with a 20% year-on-